In international trials, glucagon-like protein-1 receptor agonists (GLP-1RAs) and sodium-glucose cotransporter-2 inhibitors (SGLT2Is) were effective in improving cardiovascular (CV) outcomes.

Regional variation of effects of new antidiabetic medications in cardiovascular outcome trials / Cotter, G., Davison, B.A., Edwards, C., Senger, S., Teerlink, J.R., Zannad, F., Nielsen, O.W., Metra, M., Mebazaa, A., Chioncel, O., Greenberg, B.H., Maggioni, A.P., Ertl, G., Sato, N., Cohen-Solal, A.. - In: AMERICAN HEART JOURNAL. - ISSN 1097-6744. - 240:(2021), pp. 73-80. [10.1016/j.ahj.2021.06.001]

Regional variation of effects of new antidiabetic medications in cardiovascular outcome trials

Metra, Marco;
2021-01-01

Abstract

In international trials, glucagon-like protein-1 receptor agonists (GLP-1RAs) and sodium-glucose cotransporter-2 inhibitors (SGLT2Is) were effective in improving cardiovascular (CV) outcomes.
2021
Cardiovascular Diseases
Diabetes Mellitus
Type 2
Diabetic Nephropathies
Glucagon-Like Peptide-1 Receptor
Heart Failure
Humans
Hypoglycemic Agents
Regression Analysis
Sodium-Glucose Transporter 2 Inhibitors
Treatment Outcome
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/20.500.11768/193201
Citazioni
  • ???jsp.display-item.citation.pmc??? 2
  • Scopus 2
  • ???jsp.display-item.citation.isi??? 2
social impact